Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)

CNY 62.27

(-1.16%)

Market Cap (In CNY)

16.48 Billion

Revenue (In CNY)

385.41 Million

Net Income (In CNY)

-278.58 Million

Avg. Volume

1.69 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
33.2-79.99
PE
-
EPS
-
Beta Value
0.64
ISIN
CNE100003RP1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Zelin Sheng
Employee Count
-
Website
https://www.zelgen.com
Ipo Date
2020-01-23
Details
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.